Transcode Therapeutics, Inc.

RNAZ

—

Advanced chart & tools →

Transcode Therapeutics, Inc.RNAZ

$0.00

+$0.00(+NaN%)Past Year

Jun 25Sep 25Dec 25Mar 26Jun 26

Key statistics

Market cap

—

P/E ratio

—

EPS (diluted)

$-52.59

Dividend yield

0.00%

Dividend / share

$0.00

Revenue

—

Net income

$-34.66M

Net margin

—

Gross margin

—

Dividends & financials

Transcode Therapeutics, Inc. (RNAZ) reported revenue of — and net income of $-34.66M, or $-52.59 per diluted share. It does not currently pay a dividend. Financial figures are sourced from the company’s latest public filings; the price chart updates live, 24/7, even when the underlying market is closed.